Stepanova Ganna, Manzéger Anna, Mózes Miklós M, Kökény Gábor
Institute of Translational Medicine, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.
International Nephrology Research and Training Center, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.
Int J Mol Sci. 2024 Nov 22;25(23):12551. doi: 10.3390/ijms252312551.
Kidney fibrosis is a hallmark of chronic kidney diseases. Evidence shows that genetic variability and complement component 3 (C3) might influence tubulointerstitial fibrosis. Still, the role of renal C3 production in the epithelial-to-mesenchymal transition (EMT) and genetically determined fibrosis progression remains undiscovered. The kidneys of fibrosis-resistant C57Bl/6J (B6) and fibrosis-prone CBA/J (CBA) and BALB/cJ (BalbC) mice (n = 4-8/group) were subjected to unilateral ureteral obstruction (UUO) and analyzed after 1, 3, and 7 days, along with human focal glomerular sclerotic (FSGS) and healthy kidneys. Mouse primary tubular epithelial cells (PTECs) were investigated after 24 h of treatment with transforming growth factor β (TGFβ) or complement anaphylatoxin 3a (C3a) agonist (n = 4/group). UUO resulted in delayed kidney injury in fibrosis-resistant B6 mice, but very early renal C3 messenger RNA (mRNA) induction in fibrosis-prone CBA and BalbC mice, along with collagen I (Col1a1) and collagen III (Col3a1). CBA depicted the fastest fibrosis progression with the highest C3, lipocalin-2 (Lcn2), Tgfb1, and chemokine (C-C motif) ligand 2 (Ccl2) expression. Human FSGS kidneys depicted C3 mRNA over-expression and strong tubular C3 immunostaining. In PTECs, C3a agonist treatment induced pro-fibrotic early growth response protein 1 (EGR1) expression and the EMT, independent of TGFβ signaling. We conclude that de novo renal tubular C3 synthesis is associated with the genetically determined kidney fibrosis progression rate in mice and the pathogenesis of FSGS in humans. This tubular C3 overproduction can, through local pro-fibrotic effects, influence the progression of chronic kidney disease.
肾纤维化是慢性肾脏病的一个标志。有证据表明,基因变异性和补体成分3(C3)可能影响肾小管间质纤维化。然而,肾脏C3产生在上皮-间质转化(EMT)和基因决定的纤维化进展中的作用仍未被发现。对纤维化抗性C57Bl/6J(B6)、纤维化易感CBA/J(CBA)和BALB/cJ(BalbC)小鼠(每组n = 4 - 8只)的肾脏进行单侧输尿管梗阻(UUO),并在1天、3天和7天后进行分析,同时分析人类局灶节段性肾小球硬化(FSGS)肾脏和健康肾脏。在用转化生长因子β(TGFβ)或补体过敏毒素3a(C3a)激动剂处理24小时后,对小鼠原代肾小管上皮细胞(PTECs)进行研究(每组n = 4只)。UUO导致纤维化抗性B6小鼠的肾损伤延迟,但在纤维化易感CBA和BalbC小鼠中,肾脏C3信使核糖核酸(mRNA)很早就被诱导,同时伴有I型胶原(Col1a1)和III型胶原(Col3a1)。CBA表现出最快的纤维化进展,C3、lipocalin-2(Lcn2)、Tgfb1和趋化因子(C - C基序)配体2(Ccl2)表达最高。人类FSGS肾脏表现出C3 mRNA过表达和强烈的肾小管C3免疫染色。在PTECs中,C3a激动剂处理诱导促纤维化早期生长反应蛋白1(EGR1)表达和EMT,与TGFβ信号传导无关。我们得出结论,肾小管C3的从头合成与小鼠基因决定的肾纤维化进展速度以及人类FSGS的发病机制相关。这种肾小管C3的过度产生可通过局部促纤维化作用影响慢性肾脏病的进展。